Clinical Research Updates, CHDI Therapeutics Conference, Up & Coming HD Scientists

Clinical Trials News: positive updates from uniQure and PTC Therapeutics  

This week, we had two updates from major players in HD research, uniQure and PTC Therapeutics, on their investigational huntingtin-lowering therapies, AMT-130 and PTC518, respectively. These companies have been in the headlines in the last year not only for their unique approaches to huntingtin-lowering, but also for some pauses in study recruitment in the last year. Read the HD Buzz summary on what we know so far about each study thus far, the highlights of this week’s press releases, and next steps for the two drugs here.   

Stay tuned for more information about an upcoming HDSA research webinar with members of the uniQure team to learn more about AMT-130 and what we can expect next in its development.   

2023 CHDI Therapeutics Conference Presentations Now Available Online!  

This past February, HD researchers, clinicians, and industry professionals from across the globe gathered in Dubrovnik, Croatia, for the CHDI Therapeutics Conference. HD Buzz gave us a play by play of major highlights from the conference days one, two, and three, but now you can check out the presentations for yourself. Access recordings of all conference sessions online via CHDI’s website, here.  

Help4HD: Young HD Investigators  

Last week, the Help4HD podcast, hosted by Lauren Holder, sat down with some up-and-coming HD researchers to learn about their work and why they’ve made HD a priority in their scientific careers. Hear HDSA Human Biology Project fellow, Dr. Charlie Smith-Geater, and HDF Young Investigator Award recipient, Dr. Gung-Her Wu, discuss their research interests and future directions of their work here.